Frequently Asked Questions
Factors such as increased cases of lassa fever and growing demand for ribavirin are acting as the major drivers for the global lassa fever treatment market.
AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Bausch Health Companies Inc. (Canada).
The Lassa Fever Treatment Market will be segmented by Dosage Form, Treatment, Route of Administration, End-Users, Distribution Channel
Asia-Pacific dominates the market due to increased government awareness programs and number of generic drugs.
